Ticagrelor Market 2021 in-depth, Detailed Survey and Outlook Report Shows How Top Companies Is Able to Survive in Future Till 2031
Market Overview
The global Ticagrelor
Market is predicted to register a striking CAGR during the forecast
period (2017-2027) owing to the rising patient population suffering from heart
problems, asserts Market Research Future (MRFR). Ticagrelor is referred to as
an antiplatelet drug, a member of the pharmaceuticals section which helps to
tackle the problem of platelet aggression. It keeps the platelets from
coagulating in order to prevent unwanted blood clots that can occur with
certain blood vessel or heart conditions. Ticagrelor outperformed an established
product named Clopidogrel by the SOC in the clinical trials in terms of safety
of the patients and end results. The drug is also used as an agent to reduce
stent thrombosis. Ticagrelor is a product of an already established entity,
AstraZeneca and will be offered enough market space to achieve high growth
rates in the market.
Competitive Dashboard
The prominent
players operating the global ticagrelor market are Alexion, Ingelheim,
Roche, Ingelheim Pfizer, Pfizer, GSK, Boehringer, Amgen, Boehringer, Merck,
Amgen, and Eli Lilly.
Get Sample
Report: https://www.marketresearchfuture.com/sample_request/820
Global Ticagrelor Market: Segmental Analysis
The global
ticagrelor market has been segmented on the basis of end-users and region.
·
By mode of end-users, the global ticagrelor market has been segmented into hospitals,
clinics, and medical institutions. Among these, the hospital segment is
considered to experience a significant growth rate during the assessment period
owing to the well-developed infrastructure and latest devices offered by the
hospitals. Moreover, rising incidences of heart attacks are propelling the
segment growth.
Drivers and Constraints Impacting the Market
The global
ticagrelor market is estimated to register a healthy CAGR due to several
driving factors. With increasing patient population suffering from heart
problems, the market is estimated to foster during the assessment period.
Increasing product development by the companies, funding for research and
development activities by the major market players and improving market access
scenarios are further estimated to propel the market. Moreover, owing to the
presence of several well-established players, the ticagrelor market is
estimated to flourish in the coming years.
On the flip
side, side effects of ticagrelor such as chest pain, irregular heartbeat,
shortness of breath, nose bleeding, and spots under the skin are some of the
major concerns considered to impede the market growth during the estimated
period.
Regional Insights
Geographically,
the ticagrelor market span across regions namely, Europe, Americas, Asia
Pacific, and the Middle East & Africa.
Among all the
regions, America occupies the largest market share of approx. more than 40%
owing to the extensive use of the drug by the patients who are discharged from
hospitals in this region. Moreover, presence of major manufactures in this
region is further contributing to the market growth.
Europe is
estimated to be the second largest market and is anticipated to maintain its
dominance during the appraisal period owing to the increasing awareness of
ticagrelor in this region. Moreover, well-developed hospital infrastructure has
further promoted the market growth.
The Asia Pacific
region is considered to expand at the fastest growth rate owing to the
increased number of cardiovascular patients in this region. Economies such as
China and India are predicted to be the fastest growing regions. Moreover,
major key players are expanding their presence in this region which is further
contributing to the market growth. For instance, Sun Pharmaceutical Industries
Ltd. and AstraZeneca Pharma India Limited had announced that they had entered
entered into a distribution services agreement in India for Axcer, which is a
new brand of ticagrelor.
On the other
hand, the Middle East & Africa is presumed to occupy the least market share
owing to poor medical facilities, lack of awareness, and limited market
scenario activities.
Industry Updates
·
September 05, 2018: The US Food
and Drug Administration has recently approved the first generic medication
which has been developed forminimizing the risk of heart attack and also death
caused from heart attack in patients suffering from acute coronary syndrome. A
generic version of Brilinta from AstraZeneca Pharmaceuticals, Ticagrelor tablet
shave been granted Abbreviated New Drug Application approval in 60 and 90 mg
doses.
Browse Full
Reports: https://www.marketresearchfuture.com/reports/ticagrelor-market-820
Patient
Engagement Solutions Market Research Report - Global Forecast till 2027
Intrauterine
Contraceptive Devices (IUCDs) Market Research Report - Global Forecast till
2027
About US:
Market Research
Future (MRFR) enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson
Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment